Literature DB >> 9459509

HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group.

Z Pelin1, C Guilleminault, N Risch, F C Grumet, E Mignot.   

Abstract

Narcolepsy is a neurological disorder known to be tightly associated with HLA-DQA1*0102 and DQB1*0602. In this study, we have examined if homozygosity for DQB1*0602 increases disease susceptibility and/or severity. Patients diagnosed at Stanford University (n=160) or enrolled in a multicenter clinical trial (n=509) were included in this analysis. In both African-Americans and Caucasian-Americans with or without cataplexy, a significantly higher than expected number of subjects were DQB1*0602 homozygotes. Relative risks were 2-4 times higher in DQB1*0602 homozygotes vs heterozygotes across all patient groups. In contrast, symptom severity did not differ between DQB1*0602 homozygous and heterozygous subjects. These results indicate that HLA-DQB1*0602 homozygosity increases susceptibility to narcolepsy but does not appear to influence disease severity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9459509     DOI: 10.1111/j.1399-0039.1998.tb02952.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  24 in total

Review 1.  Narcolepsy: immunological aspects.

Authors:  Sebastiaan Overeem; John Logan Black; Gert Jan Lammers
Journal:  Sleep Med Rev       Date:  2008-03-04       Impact factor: 11.609

2.  Challenges in diagnosing narcolepsy without cataplexy: a consensus statement.

Authors:  Christian R Baumann; Emmanuel Mignot; Gert Jan Lammers; Sebastiaan Overeem; Isabelle Arnulf; David Rye; Yves Dauvilliers; Makoto Honda; Judith A Owens; Giuseppe Plazzi; Thomas E Scammell
Journal:  Sleep       Date:  2014-06-01       Impact factor: 5.849

Review 3.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

4.  HLA dosage effect in narcolepsy with cataplexy.

Authors:  Astrid van der Heide; Willem Verduijn; Geert W Haasnoot; Jos J M Drabbels; Gert J Lammers; Frans H J Claas
Journal:  Immunogenetics       Date:  2014-10-03       Impact factor: 2.846

Review 5.  Human leukocyte antigen gene polymorphism and the histocompatibility laboratory.

Authors:  T M Williams
Journal:  J Mol Diagn       Date:  2001-08       Impact factor: 5.568

Review 6.  Clinical and neurobiological aspects of narcolepsy.

Authors:  Seiji Nishino
Journal:  Sleep Med       Date:  2007-04-30       Impact factor: 3.492

Review 7.  Benefits and risks of pharmacotherapy for narcolepsy.

Authors:  Merrill M Mitler; Roza Hayduk
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 8.  Genetic Ancestry for Sleep Research: Leveraging Health Inequalities to Identify Causal Genetic Variants.

Authors:  Bharati Prasad; Richa Saxena; Namni Goel; Sanjay R Patel
Journal:  Chest       Date:  2018-03-28       Impact factor: 9.410

9.  HLA DQB1*06:02 negative narcolepsy with hypocretin/orexin deficiency.

Authors:  Fang Han; Ling Lin; Barbara Schormair; Fabio Pizza; Giuseppe Plazzi; Hanna M Ollila; Sona Nevsimalova; Poul Jennum; Stine Knudsen; Juliane Winkelmann; Cristin Coquillard; Farbod Babrzadeh; Tim M Strom; Chunlin Wang; Michael Mindrinos; Marcelo Fernandez Vina; Emmanuel Mignot
Journal:  Sleep       Date:  2014-10-01       Impact factor: 5.849

Review 10.  Genetic and immunologic aspects of sleep and sleep disorders.

Authors:  James M Parish
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.